Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Want to see ABOS full AI Analyst Report?
Top Page
Acumen Pharmaceuticals
(NASDAQ:ABOS)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▼(-11.35% Downside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by very weak financial performance (no revenue, widening losses, and accelerating cash burn with declining equity). Technical indicators also reflect a weak trend with heavy selling pressure. These negatives are partially offset by the earnings call’s positive clinical/preclinical progress, clear milestones, and recent financing that extends runway into early 2027.
Positive Factors
Clinical biomarker progress
Positive Phase Ib CSF biomarker changes indicate sabirnetug engages disease biology, which materially de-risks later-stage proof points. Durable target engagement data strengthens the credibility of the Phase II program, supporting regulatory dialogue and potential partner interest over the next 2–6 months.
Negative Factors
Pre-revenue with widening losses
No commercial revenue and materially expanding net losses make the business dependent on external capital. Persistent pre-revenue status and accelerating losses erode equity, increase dilution risk, and constrain strategic optionality unless clinical programs rapidly re-price program value.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical biomarker progress
Positive Phase Ib CSF biomarker changes indicate sabirnetug engages disease biology, which materially de-risks later-stage proof points. Durable target engagement data strengthens the credibility of the Phase II program, supporting regulatory dialogue and potential partner interest over the next 2–6 months.
Read all positive factors
Acumen Pharmaceuticals (ABOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$171.90M
Dividend YieldN/A
Average Volume (3M)415.59K
Price to Earnings (P/E)―
Beta (1Y)2.18
Revenue GrowthN/A
EPS Growth-17.56%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.02
Shares Outstanding72,227,580
10 Day Avg. Volume506,634
30 Day Avg. Volume415,590
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.83K
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$8.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Acumen Pharmaceuticals Business Overview & Revenue Model
Company Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoc...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Acumen Pharmaceuticals does not have an established recurring product-revenue base from marketed drugs; commercial sales revenue is null. The company’s funding and cash inflows are primarily tied to f...
Acumen Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Neutral
The call conveyed strong scientific and preclinical progress (notably positive Phase Ib biomarkers for sabirnetug and robust EBD preclinical exposure gains of 14–40x), plus committed financing to advance the EBD program. At the same time, the company faces substantial ongoing R&D spend, a large 2025 net loss ($121.3M), and a relatively limited cash runway into early 2027, implying likely future financing needs and continued reliance on upcoming ALTITUDE-AD readout (late 2026) to de-risk the program. Overall, the positives around clinical momentum and preclinical differentiation are balanced by material financial and execution risks.Positive Updates
Phase II ALTITUDE-AD Progress and Enrollment
Completed enrollment ~1 year ago for the 18-month ALTITUDE-AD Phase II study; participant transition into the 12-month open-label extension (OLE) started November 2025 is smooth with a high rollover/conversion rate and retention metrics in line with other major AD trials.
Negative Updates
Large Net Loss and High R&D Spend
Reported a net loss of $121.3 million for 2025 with R&D expenses of $104.9 million (increase year-over-year driven by manufacturing/materials for ALTITUDE-AD, personnel and EBD research), reflecting substantial cash burn from clinical development.
Read all updates
Q4-2025 Updates
Positive
Negative
Phase II ALTITUDE-AD Progress and Enrollment
Completed enrollment ~1 year ago for the 18-month ALTITUDE-AD Phase II study; participant transition into the 12-month open-label extension (OLE) started November 2025 is smooth with a high rollover/conversion rate and retention metrics in line with other major AD trials.
Read all positive updates
Company Guidance
Acumen provided clear near‑term and programmatic guidance: it expects the Phase II ALTITUDE‑AD readout late 2026 (ALTITUDE is an 18‑month, well‑powered trial with enrollment completed ~1 year ago and a high retention/rollover rate into the 12‑month open‑label extension that began November 2025), and noted Phase Ib INTERCEPT biomarker activity (CSF pTau181 and neurogranin changes after three doses at the 3‑month timepoint and some plaque reduction at the highest doses — 60 mg/kg and 25 mg/kg — comparable to lecanemab at 3 months); the OLE is dosing at 35 mg/kg. For the EBD program they plan an IND in mid‑2027 after preclinical data showing nonhuman primate brain levels 14‑ to 40‑fold higher versus native antibody at 24 hours, no 24‑hour changes in RBC count/hematocrit/hemoglobin/reticulocytes, stability supportive of low‑volume subcutaneous dosing, and multiple candidates exceeding the target profile; a March 16, 2026 private placement grossed $35.75M to primarily support EBD. FY‑2025 financials: $116.9M cash and marketable securities at year‑end, R&D expense $104.9M, G&A $18.9M, net loss $121.3M, with cash runway expected into early 2027.Acumen Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -184.00K | 0.00 | 0.00 | -169.00K | -12.30M |
| EBITDA | -123.83M | -98.08M | -51.61M | -42.69M | -19.58M |
| Net Income | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M |
Balance Sheet | |||||
| Total Assets | 122.83M | 238.99M | 310.13M | 196.59M | 230.33M |
| Cash, Cash Equivalents and Short-Term Investments | 116.86M | 171.56M | 243.52M | 177.60M | 194.24M |
| Total Debt | 31.31M | 29.70M | 28.49M | 105.00K | 0.00 |
| Total Liabilities | 52.40M | 57.18M | 43.15M | 7.81M | 5.15M |
| Stockholders Equity | 70.43M | 181.82M | 266.97M | 188.78M | 225.18M |
Cash Flow | |||||
| Free Cash Flow | -115.63M | -86.23M | -43.09M | -35.31M | -18.00M |
| Operating Cash Flow | -115.54M | -86.22M | -43.06M | -35.15M | -17.96M |
| Investing Cash Flow | 133.93M | 48.03M | -171.67M | 39.19M | -104.12M |
| Financing Cash Flow | -34.00K | 6.93M | 151.75M | 3.91M | 200.47M |
Acumen Pharmaceuticals Technical Analysis
Positive
2.82
Price Trends
2.77
Positive
2.41
Positive
2.01
Positive
Market Momentum
-0.03
Negative
55.31
Neutral
74.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Positive. The current price of 2.82 is above the 20-day moving average (MA) of 2.58, above the 50-day MA of 2.77, and above the 200-day MA of 2.01, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 55.31 is Neutral, neither overbought nor oversold. The STOCH value of 74.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABOS.
Acumen Pharmaceuticals Risk Analysis
Acumen Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Acumen Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acumen Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $385.95M | -0.70 | 610.83% | ― | -67.37% | -74.49% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $252.18M | -3.96 | -46.90% | ― | ― | 77.80% | |
49 Neutral | $73.32M | -1.00 | -79.36% | ― | 266.65% | 12.67% | |
47 Neutral | $24.79M | -0.37 | ― | ― | ― | ― | |
45 Neutral | $171.90M | -1.27 | -111.27% | ― | ― | -17.56% |
* Healthcare Sector Average
ABOS
Acumen Pharmaceuticals
2.48
1.44
138.46%
VTGN
VistaGen Therapeutics
0.62
-1.73
-73.53%
IKT
Inhibikase Therapeutics
1.94
-0.15
-7.18%
SRZN
Surrozen
32.07
21.82
212.88%
TCRX
TScan Therapeutics
1.22
-0.28
-18.67%
Acumen Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027
Positive
Mar 26, 2026
On March 26, 2026, Acumen Pharmaceuticals reported full-year 2025 results and updated investors on progress in its Alzheimer’s pipeline, highlighting ongoing Phase 2 development of sabirnetug and expansion of its Enhanced Brain Delivery plat...
Business Operations and StrategyPrivate Placements and Financing
Acumen Raises Capital to Advance Enhanced Brain Delivery
Positive
Mar 16, 2026
On March 13, 2026, Acumen Pharmaceuticals agreed to sell 10,833,331 common shares at $3.30 each in a private placement to institutional accredited investors, raising expected gross proceeds of about $35.75 million to support its Enhanced Brain Del...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.